A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

December 29, 2023

Study Completion Date

December 29, 2023

Conditions
HealthyLiver DiseasesObesity
Interventions
DRUG

BI 456906

BI 456906

Trial Locations (13)

1010

New Zealand Clinical Research (NZCR), Auckland

1083

Semmelweis University, Budapest

2140

CRU Hungary Ltd., Kistarcsa

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

33912

Covenant Metabolic Specialists, LLC, Fort Myers

34240

Covenant Metabolic Specialists, LLC, Sarasota

51162

Dr. Piotr Napora, Center of Clinical Research, Wroclaw

53127

Universitätsklinikum Bonn AöR, Bonn

78215

American Research Corporation at the Texas Liver Institute, San Antonio

78229

IMA Clinical Research San Antonio, San Antonio

83101

SUMMIT CLINICAL RESEARCH, s.r.o., Bratislava

85224

Arizona Liver Health, Chandler

89081

Universitätsklinikum Ulm, Ulm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY